902 results about "Liver fibrosis" patented technology

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

This invention concerns the method of extracting salvianolic acid A from Chinese crude drug: danshen root, and the quality control methods and drug combinations, and the application of this drug. It can be used in the preparation of the prevention drugs for cardiovascular disease, liver damage, liver fibrosis, pulmonary fibrosis and other.

An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and / or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected froma. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis,d. cancer, e.g. cancer / hemangioendothelioma proliferation, gastric carcinomas,e. metabolic diseases, e.g. hypertension,f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection / graft failure / graft vasculopathy, HIV infections / AIDS, gestosis, tuberous sclerosis.Additionally disclosed are a respective diagnostic method, assay and kit.

The present invention provides a method of diagnosing the presence or severity of liver fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of liver fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1.

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and / or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.

The invention discloses a sgRNA specifically targeting human RSPO2 gene in a CRISPR-Cas9 system and an activation method and application thereof, and belongs to the field of biotechnology. The CRISPR-Cas9 system specifically activates the expression of the human RSPO2 gene, and introduces the activity of human hepatic stellate cells to activate Wnt signaling pathway so as to significantly upregulate the expression of liver fibrosis markers alpha-SMA and Collagen I. The CRISPR-Cas9 system designed for RSPO2 gene targets can effectively activate the hepatic stellate cells, thereby providing an effective way for liver fibrosis research.

The invention provides a Tibetan virgate wormwood herb extract containing swertiamain, gentiopicroside, sweroside, mangiferin and isoorientin, and the weight ratio of the five ingredients is (0.04-0.71): (20-40): (1-15): (1.6-26): (0.01-0.16). The invention further provides a preparation method of the Tibetan virgate wormwood herb extract, a pharmaceutical composition containing the Tibetan virgate wormwood herb extract and a medical use of the Tibetan virgate wormwood herb extract. The Tibetan virgate wormwood herb extract can improve various indicators caused by liver injury, promote the reversal of the liver fibrosis process and better prevent liver cirrhosis.

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

The invention relates to magnetic resonance elastography detection system and method thereof. The detection system comprises a high-field nuclear magnetic resonance whole body imaging system which can carry out liver imaging, and a shear wave excitation device. The detection method comprises the following steps of: (1) inner particle displacement on a phantom or a detected part; (2) magnetic resonance elastography forming; and (3) fibration classification. For preliminary experiments on the phantom as well as studies on background phase noise and experiment researches on the relationship between shear wave transmission and shear wave frequency, the invention has good image quality and obvious effect. The invention establishes a foundation for subsequent MRE researches on the liver tissue, and provides directions and references for elastic researches on other parts.

The invention discloses a composition for monitoring liver cancer or liver fibrosis risks, which is prepared from the following N-oligosaccharide chains: NA3F, NA2F, NA2FB, NA2G, NA2GF, NGA2F, NGA2FB and NA3. The composition can be used for preparing a reagent which is used for liver cancer early-diagnosis, liver cancer staging detection or prognosis assessment and can also be applied to liver fibrosis early-diagnosis or prognosis assessment. The invention also provides a method for monitoring liver cancer or liver fibrosis risks. According to the method, the sensitivity and stability of liver cancer or liver fibrosis diagnosis can be greatly increased. The method is greatly superior to the current AFP (alpha fetoprotein) detecting technique.

Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the invention the fibrosis is liver fibrosis.

The present invention is drawn to a new diagnosis method for detecting the extent of alcoholic or non-alcoholic steato-hepatitis in a patient, in particular in a patient suffering from a disease involving alcoholic or non-alcoholic steato-hepatitis or who already had a positive diagnosis test of liver fibrosis and / or presence of liver necroinflammatory lesions, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.

Methods and kits for determining predisposition of an individual to develop fast progression rate of liver fibrosis are provided. Also provided are agents and pharmaceutical compositions useful in preventing fast progression of liver fibrosis and a method of identifying drug molecules which accelerate or induce liver fibrosis.

The invention relates to an application of an earthworm fibrinolytic enzyme in preparation of liver fibrosis resistant medicine or liver protection health-care food, which belongs to the technical field of biology. The effective dose of an oral liver fibrosis resistant earthworm fibrinolytic enzyme is 1,000-3,000 urokinase unit / person / day. Proved by experiments, earthworm collagenase can degrade collagen but cannot degrade (ox blood) fibrin, and the earthworm fibrinolytic enzyme can degrade the (ox blood) fibrin and can also degrade the collagen, thus the activity of the earthworm fibrinolytic enzyme is higher than the activity of the earthworm collagenase and the activity of a collagenase standard product (Sigma I type). Proved by a liver fibrosis resistant experiment by using a rat, the oral liver fibrosis resistant earthworm fibrinolytic enzyme has obvious effect and no obvious poisonous and side effect, but the oral liver fibrosis resistant earthworm collagenase does not have obvious effect.

This invention relates to method of diagnosing the presence and / or severity of a liver pathology and / or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function.This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

The present invention provides methods for treating alphavirus infections; methods of treating hepatitis C virus (HCV) infections; methods of treating West Nile virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering effective amounts of an interferon receptor agonist and pirfenidone in combination therapy.

An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and / or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.

The invention provides methods and kits to detect liver fibrosis or a change in the gradation of liver fibrosis in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum.

The present invention is concerned with a method for differentiating between liver fibrosis and liver cirrhosis in a subject based on the determination of growth differentiation factor 15 (GDF-15), hepatocyte growth factor (HGF) and / or endoglin in a sample of a subject and comparing the thus determined amount with a reference amount (reference amounts). Further envisaged by the present invention are kit and a device adapted to carry out the method of the present invention.

A type IV collagen high molecular form having a higher molecular weight than the 7S domain of type IV collagen and including the 7S domain in its structure, is obtained from the supernatant being recovered from a collagen solution digested by pepsin in the following steps; 1) salt precipitating with sodium chloride at a concentration no higher than 1.2 M, 2) dissolving the precipitates, 3) salt precipitating with sodium chloride at a concentration no higher than previous concentration. By reacting a sample with an antibody which reacts with this form, the type IV collagen high molecular form in the sample can be measured to allow diagnosis of the degree of liver fibrosis in patients with liver diseases.

The invention belongs to the technical field of medical image processing and computer vision, and particularly relates to an MRI image liver fibrosis automatic grading method based on imaging omics analysis. The invention particularly relates to an imaging omics analysis method for grading magnetic resonance dynamic enhanced imaging liver fibrosis of a Gd-EOB-DTPA contrast agent. The method comprises the following steps: establishing an initial data set by taking a Gd-EOB-DTPA dynamic enhanced image of a hepatitis B patient as source data; registering the initial data; carrying out automatic liver segmentation by utilizing transfer learning to obtain an ROI; performing image omics analysis: for the ROI, carrying out image omics feature extraction and feature screening on a plurality of DCEsequences to obtain a feature subset of important features, and carrying out training of a plurality of classifiers to select an optimal classifier; and finally, predicting and evaluating the classification performance in an external test set by using the classifier. According to the method, the accuracy and reliability of automatic liver fibrosis grading based on DCE images can be effectively improved, and meanwhile, the time and energy of clinicians are saved to a great extent.

The present invention relates to monoclonal antibody HAb18GC2 and its variable area gene of its heavy chain and light chain and polypeptide, and their uses in preparing therapeutic agent for reversing hepatic fibrosis etc. matrix deposition disease. The present monoclonal antibody HAb18GC2 can bind specificly with antibody HAb18G / CD147 highly expressed in human liver fibrosis tissue and with liver astrocyte and possesses function of facilitating MMPs secretion and reducing the extracellular matrix. The antibody light, heavy chain variable area genes are successfully cloned in the present invention and small molecule gene engineered antibodies of all kinds are constructed and expressed based on the gene for preparing drug for reversing liver fibrosis matrix deposition-related disease. The polypeptide coded by the present gene can crosslink with multiple effector molecule and prepare drug for reversing liver fibrosis matrix deposition-related disease.